Glioblastoma

Glioblastoma (GBM) is the most aggressive and common primary malignant brain tumor in adults. Arising from astrocytes, these tumors are characterized by rapid, infiltrative growth, extensive necrosis, and microvascular proliferation. Despite aggressive multimodal therapy, prognosis remains poor due to intrinsic resistance to treatment and systemic invasion within the central nervous system.

Most GBM cases are sporadic with no clear identifiable cause. Genetic mutations, including IDH-wildtype status, TP53 mutations, and EGFR amplification, are central. Environmental triggers are poorly defined, though high-dose ionizing radiation is the only established exogenous risk factor.

GBM originates from neural stem cells or glial progenitor cells. It is defined by rapid cellular proliferation, pseudopalisading necrosis, and robust neoangiogenesis, driven by vascular endothelial growth factor (VEGF). The tumor infiltrates healthy brain tissue via white matter tracts, making surgical "cure" nearly impossible.

GBM accounts for approximately 15% of all primary brain tumors. The annual incidence is 3.19 per 100,000 population. It is more common in males than females and typically diagnosed between ages 60 and
75.

Age, male sex, white ethnicity, exposure to ionizing radiation, and rare genetic syndromes (e.g., Li-Fraumeni, Neurofibromatosis Type 1).

A. Early Symptoms: Morning headaches, mild cognitive changes, personality shifts.
B. Common Symptoms: Focal neurological deficits, hemiparesis, localized sensory loss, aphasia.
C. Advanced Symptoms: Severe intracranial pressure symptoms, personality disintegration, cognitive decline.
D. Emergency Symptoms: New-onset focal or generalized seizures, rapidly worsening level of consciousness, stroke-like deficits.

Papilledema (increased ICP), focal motor/sensory deficits, gait ataxia, cranial nerve palsies, and altered mental status.

A. Clinical Assessment: Neurological examination, mental status screening.
B. Laboratory Testing: CBC and electrolytes to rule out metabolic mimics.
C. Imaging Studies: Gadolinium-enhanced MRI is the gold standard.
D. Functional Tests: fMRI for surgical mapping.
E. Biopsy Findings: Necrotic tissue, high mitotic index, microvascular proliferation.
F. Genetic Testing: IDH mutation status, MGMT promoter methylation, EGFRvIII.
G. Differential Diagnosis: Brain metastases, abscesses, lymphoma, demyelinating disease.

Complete Blood Count (CBC)
Type: Blood Test
Purpose: Baseline health assessment
Expected Findings: Normal or leukocytosis
Interpretation: Indicates systemic inflammatory response

Contrast-Enhanced MRI: Shows "ring-enhancing" lesion with central necrosis and surrounding edema. Critical for surgical planning and monitoring.

Brain Metastases (usually multiple), Cerebral Abscess (diffusion restriction), Primary CNS Lymphoma (homogeneously enhancing).

Seizures, venous thromboembolism, cognitive impairment, treatment-related myelosuppression.

A. Lifestyle Modifications: Diet optimization, caregiver support.
B. Preventive Measures: None established.
C. Medical Treatment: Temozolomide (alkylating agent), Bevacizumab (VEGF inhibitor).
D. Surgical Treatment: Maximal safe resection.
E. Interventional Procedures: Tumor Treating Fields (TTFields).
F. Rehabilitation: Occupational and speech therapy.
G. Emergency Management: Dexamethasone for edema, anti-epileptic drugs (Levetiracetam).

Median survival is 15–18 months with standard care; five-year survival rate is approximately 5-10%.

None; primary prevention is not currently possible.

The following homeopathic remedies have been historically indicated for symptoms associated with Glioblastoma. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Glioblastoma.